Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Akt inhibitor NTQ1062

An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon oral administration, Akt inhibitor NTQ1062 targets, competitively binds to and inhibits the activity of Akt, which may result in the inhibition of the PI3K/Akt signaling pathway, thereby leading to the inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	NTQ 1062 NTQ-1062 NTQ1062

Akt inhibitor NTQ1062

Search NCI's Drug Dictionary